TB Online is no longer maintained. This is an archive of the site. For news on TB please go to:
https://globaltbcab.org/Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313, in tuberculosis
Imaxio
Sept. 3, 2013, 8:21 p.m.
IMX313, Imaxio’s antigen re-engineering technology, has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial managed by the Jenner Institute at Oxford University.
Read the press release here.
Source: Imaxio